Venetoclax

Venetoclax

API’s Name:Venetoclax 

CAS No.:1257044-40-8

Indication:CLL

Innovator:Abbvie

Specification

Patent Expiry Date(The U.S):Jun.27,2031

US DMF

EU DMF

CEP

Only for R&D purpose

Product Detail

Intermediates

Code

CAS

Specification

VCL-6A

98549-88-3

In-House

VCL-7A

1235865-75-4

In-House

VCLM2

1228780-72-0

In-House

VCLM2-2HCl

1628047-87-9

In-House

VCLM3

1228779-96-1

In-House


Generic Name: venetoclax (ven ET oh klax)

Brand Name: Venclexta, Venclexta Starting Pack

Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.

Venetoclax is used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions.

Venetoclax is sometimes given after other treatments have failed.

Venetoclax may also be used for purposes not listed in this medication guide.


Description

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.


In Vitro

Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC50=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC50=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC50=3 nM) but is much less effective against BCL-XL-BCL-XS (EC50=2.2 μM) or MCL-1-NOXA complexes.

After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGImax) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)[1].

Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.

Storage

Powder

-20°C

3 years

4°C

2 years
In solvent

-80°C

6 months

-20°C

1 month



Chemical structure

Venetoclax 1257044-40-8